ABBV/ENTA's second-generation HCV regimen* gets FDA BTD for GT1 DAA-treatment failures: http://finance.yahoo.com/news/abbvies-investigational-hcv-regimen-receives-120000049.html Please see #msg-122031014 for the global phase-3 program for this regimen. *ABT-493 (PI) + ABT-530 (NS5A).